Disintegrin variants and pharmaceutical uses thereof

Woei-Jer Chuang (Inventor)

Research output: Patent

Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
Original languageEnglish
Patent number291711
Publication statusPublished - 2009 Oct 13

Fingerprint

Disintegrins
Integrins
Pharmaceutical Preparations
Peptides

Cite this

@misc{60a1162baac64d689d2ae1e40a10f06e,
title = "Disintegrin variants and pharmaceutical uses thereof",
abstract = "Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.",
author = "Woei-Jer Chuang",
year = "2009",
month = "10",
day = "13",
language = "English",
type = "Patent",
note = "291711",

}

TY - PAT

T1 - Disintegrin variants and pharmaceutical uses thereof

AU - Chuang, Woei-Jer

PY - 2009/10/13

Y1 - 2009/10/13

N2 - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

AB - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

M3 - Patent

M1 - 291711

ER -